[go: up one dir, main page]

CL2007003395A1 - Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular. - Google Patents

Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.

Info

Publication number
CL2007003395A1
CL2007003395A1 CL200703395A CL2007003395A CL2007003395A1 CL 2007003395 A1 CL2007003395 A1 CL 2007003395A1 CL 200703395 A CL200703395 A CL 200703395A CL 2007003395 A CL2007003395 A CL 2007003395A CL 2007003395 A1 CL2007003395 A1 CL 2007003395A1
Authority
CL
Chile
Prior art keywords
leucomalacy
agomelatin
periventricular
obtaining
treatment
Prior art date
Application number
CL200703395A
Other languages
English (en)
Inventor
Spedding Elisabeth Moc Michael
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38229589&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007003395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of CL2007003395A1 publication Critical patent/CL2007003395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL200703395A 2006-11-24 2007-11-22 Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular. CL2007003395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0610294A FR2908994B1 (fr) 2006-11-24 2006-11-24 Utilisation de l'agomelatine pour l'obtention de medicaments destines au traitement de la leucomalacie periventriculaire

Publications (1)

Publication Number Publication Date
CL2007003395A1 true CL2007003395A1 (es) 2008-09-12

Family

ID=38229589

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200703395A CL2007003395A1 (es) 2006-11-24 2007-11-22 Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.

Country Status (37)

Country Link
US (1) US20080125493A1 (es)
EP (1) EP1927351B1 (es)
JP (1) JP4870062B2 (es)
KR (1) KR100976000B1 (es)
CN (1) CN101185644B (es)
AR (1) AR063895A1 (es)
AT (1) ATE483458T1 (es)
AU (1) AU2007234600B2 (es)
BR (1) BRPI0704179A (es)
CA (1) CA2610637C (es)
CL (1) CL2007003395A1 (es)
CY (1) CY1110875T1 (es)
DE (1) DE602007009627D1 (es)
DK (1) DK1927351T3 (es)
EA (1) EA014067B1 (es)
ES (1) ES2353128T3 (es)
FR (1) FR2908994B1 (es)
GE (1) GEP20094747B (es)
HR (1) HRP20100680T1 (es)
JO (1) JO2631B1 (es)
MA (1) MA29522B1 (es)
ME (1) ME01866B (es)
MX (1) MX2007014004A (es)
MY (1) MY145925A (es)
NO (1) NO338598B1 (es)
NZ (1) NZ563683A (es)
PE (1) PE20081158A1 (es)
PL (1) PL1927351T3 (es)
PT (1) PT1927351E (es)
RS (1) RS51494B (es)
SG (1) SG143202A1 (es)
SI (1) SI1927351T1 (es)
TW (1) TW200829236A (es)
UA (1) UA94043C2 (es)
UY (1) UY30703A1 (es)
WO (1) WO2008071869A2 (es)
ZA (1) ZA200710102B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2810647A1 (en) * 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2003011271A2 (en) * 2001-08-03 2003-02-13 Children's Medical Center Corporation Methods and compositions for modulating brain damage
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
US7358395B2 (en) * 2005-08-03 2008-04-15 Les Laboratories Servier Crystalline form V of agomelatine, a process for its preparation and pharmaceutical compositions containing it

Also Published As

Publication number Publication date
KR100976000B1 (ko) 2010-08-17
ES2353128T3 (es) 2011-02-25
MY145925A (en) 2012-05-15
DK1927351T3 (da) 2011-01-10
EA200702317A1 (ru) 2008-06-30
WO2008071869A3 (fr) 2008-08-14
AU2007234600A1 (en) 2008-06-12
GEP20094747B (en) 2009-07-27
CN101185644B (zh) 2011-08-10
WO2008071869A2 (fr) 2008-06-19
ZA200710102B (en) 2008-11-26
UA94043C2 (ru) 2011-04-11
CA2610637A1 (fr) 2008-05-24
PL1927351T3 (pl) 2011-01-31
RS51494B (sr) 2011-04-30
ME01866B (me) 2011-04-30
AU2007234600B2 (en) 2012-05-17
EP1927351A1 (fr) 2008-06-04
CY1110875T1 (el) 2015-06-10
KR20080047298A (ko) 2008-05-28
DE602007009627D1 (de) 2010-11-18
SI1927351T1 (sl) 2010-12-31
TW200829236A (en) 2008-07-16
FR2908994A1 (fr) 2008-05-30
JO2631B1 (en) 2012-06-17
HK1118216A1 (en) 2009-02-06
BRPI0704179A (pt) 2008-07-08
EP1927351B1 (fr) 2010-10-06
JP2008133279A (ja) 2008-06-12
US20080125493A1 (en) 2008-05-29
ATE483458T1 (de) 2010-10-15
MA29522B1 (fr) 2008-06-02
JP4870062B2 (ja) 2012-02-08
SG143202A1 (en) 2008-06-27
CA2610637C (fr) 2011-04-19
HRP20100680T1 (hr) 2011-01-31
NO20076002L (no) 2008-05-26
AR063895A1 (es) 2009-02-25
PE20081158A1 (es) 2008-10-04
NO338598B1 (no) 2016-09-12
AU2007234600A8 (en) 2010-12-02
UY30703A1 (es) 2008-01-02
NZ563683A (en) 2009-04-30
MX2007014004A (es) 2009-02-16
EA014067B1 (ru) 2010-08-30
PT1927351E (pt) 2010-10-27
FR2908994B1 (fr) 2009-04-03
CN101185644A (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
HUS1600048I1 (hu) Készítmény Fabry-kór kezelésére
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
CL2007002974A1 (es) Compuestos derivados de benzoimidazol; composicion farmaceutica; y uso para el tratamiento de trastornos asociados con dgat1.
CL2007001040A1 (es) Proceso para la preparacion de antagonista de la sustancia p derivado de acil-amino-alquilen-amida.
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
BRPI1012993A2 (pt) "uso de um anticorpo anti-tau ps422 para o tratamento de doenças do cérebro"
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
CL2007002837A1 (es) Uso de fenitoina para tratar mucositis oral.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
BRPI0912539A2 (pt) composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0818170A2 (pt) 5-cianotienopiridinas para o tratamento de tumores.
BRPI0912687A2 (pt) uso de bactéria probiótica para o tratamento de hiperhomocisteinaemia
BRPI0720323A2 (pt) composto, método de tratamento, composição farmacêutica e uso do composto
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
PT2056805E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de reacção tecidular
BRPI0919694A2 (pt) composto, composto farmacêutica, uso de um composto, e, método de tratamento de uma doença.
BRPI0907956A2 (pt) Uso de ranolazina para o tratamento de doenças cardiovasculares
BRPI0911515A2 (pt) dispositivos formadores rotatórios e métodos para o uso de tais dispositivos.
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
CL2007003395A1 (es) Uso de agomelatina para la obtencion de medicamentos destinados al tratamiento de leucomalacia periventricular.